Cancer
Endpoints News reported that Genmab’s Rina-S had a 45.9% objective response rate in patients with platinum-resistant ovarian cancer.
The original reports on this story are listed below.
Research
Optogenetics is mostly a research tool, but researchers are testing it as a treatment for vision loss from retinitis pigmentosa.
Medicare and Medicaid
Eligible Medicare Part B enrollees will get a one-time $90 payment in October, but Medicare Advantage members are excluded.
Infectious disease
WHO said the worker’s cause of death has not been confirmed, contacts have shown no symptoms to date, and the risk to the general population appears low.